HCPCS Code J9228: Injection Ipilimumab, 1 mg

HCPCS Code J9228 covers injection ipilimumab 1 mg for cancers. Learn billing, documentation, and related codes.

## **What is an ipilimumab injection?** HCPCS code J9228 describes the injection of ipilimumab, 1 mg, a monoclonal antibody used in adult and pediatric patients for the treatment of various cancers, including unresectable or metastatic melanoma, advanced renal cell carcinoma, metastatic colorectal cancer, metastatic or recurrent non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma. Ipilimumab or its brand name Yervoy works by targeting CTLA-4, helping the immune system attack cancer cells. It is often used as first-line treatment or in combination therapy with other agents such as nivolumab and may be administered via intravenous infusion in cycles based on the patient’s diagnosis, clinical trial data, and medical necessity. Clinical use is guided by FDA-approved labeling and may require prior mismatch repair-deficient or microsatellite instability-high testing in certain conditions. Common adverse reactions include immune-mediated colitis, hepatitis, pneumonitis, endocrinopathies, and nephritis, requiring close monitoring by healthcare providers. Use in patients with active autoimmune disease is generally avoided due to the risk of severe immune-mediated adverse events. ### **Key uses and common reactions of ipilimumab** Ipilimumab is often part of adjuvant treatment following surgery or radiation therapy in certain cancers, especially when there is pathologic involvement of a lymph node. It targets immune checkpoints to help the body attack cancer cells. However, providers should be aware of the most common adverse reactions, which may include abdominal pain, fatigue, rash, immune mediated hepatitis, decreased weight, and inflammation in other and unspecified parts of the body. Careful monitoring helps ensure the benefits outweigh potential risks.

## **HCPCS code J9228 documentation requirements** Accurate documentation is essential when billing HCPCS code J9228 for injection ipilimumab 1 mg. Records should clearly state the diagnosis (e.g., unresectable or metastatic melanoma, advanced renal cell carcinoma, metastatic colorectal cancer, malignant pleural mesothelioma, metastatic or recurrent NSCLC), along with treatment intent (first-line, adjuvant, or combination therapy). Key elements to include are: - **Patient eligibility**: Adult or pediatric status, relevant FDA-approved test results for conditions such as mismatch repair deficiency or microsatellite instability-high. - **Dosage and administration**: Document total mg administered, infusion intervals, single dose vial usage, and whether used in combination therapy. - **Medical necessity**: Justify use with disease stage, baseline ECOG performance status, and prior treatments received. - **Adverse event monitoring**: Note any immune-mediated colitis, hepatitis, pneumonitis, endocrinopathies, or other serious adverse reactions, and describe management. - **Treatment timelines:** Include start date, whichever occurs earlier criteria for discontinuation, and confirmation of ongoing clinical benefit. - **Supporting evidence**: Reference clinical trial data, confirmatory trials, or accelerated approval rationale when applicable. Properly maintaining these records supports Medicare coverage, meets medical necessity requirements, and helps prevent claim denials.

## **J9228 billing requirements** When billing HCPCS code J9228 for injection ipilimumab 1 mg, follow these key points: - **Billing unit:** Report per 1 mg administered; round appropriately and document total dosage. - **Drug details**: Include NDC number, strength, and quantity on the claim. - **Diagnosis codes**: Use ICD-10 codes that match the FDA-approved or CMS-covered indications (e.g., unresectable malignant melanoma, advanced renal cell carcinoma, metastatic colorectal cancer, malignant pleural mesothelioma, metastatic NSCLC). - **Place of service**: Typically billed in hospital outpatient or physician office settings. - **Revenue code**: Use the correct drug revenue code (e.g., 0636 for drugs requiring detailed coding). - **Modifiers**: Append modifiers if the service is related to clinical trial participation or reduced dosage. - **Documentation linkage:** Claims must connect the administered dosage to the documented medical necessity and diagnosis. - **Payer-specific guidance**: Check individual Medicare Administrative Contractor (MAC) or private insurer policies for pre-authorization or step therapy requirements.

## **Other relevant codes** - **J9299:** Nivolumab injection (commonly used with ipilimumab), 1 mg - **J9999:** Not otherwise classified, antineoplastic drug

Frequently asked questions

HCPCS Code J9228 is used for ipilimumab treatment in cancers such as unresectable or metastatic melanoma, renal cell carcinoma, non-small cell lung cancer, and malignant pleural mesothelioma.

Yes. J9228 may be billed when ipilimumab is administered alongside other agents, such as nivolumab, provided documentation supports medical necessity.

Common reactions include immune-mediated colitis, hepatitis, pneumonitis, endocrinopathies, and infusion-related reactions, which should be recorded in the patient’s chart.